What question did this study set out to answer?

To evaluate the feasibility and immunologic effects of targeting HER-2/neu using pulsed DC1 dendritic cells with staged interleukin-12 secretion prior to surgery in patients with ductal carcinoma in situ.

February 9, 2007Cancer ResearchOpen Access

Targeting HER-2/ neu in Early Breast Cancer Development Using Dendritic Cells with Staged Interleukin-12 Burst Secretion

View Full Paper

Ask AI

Bookmark

To evaluate the feasibility and immunologic effects of targeting HER-2/neu using pulsed DC1 dendritic cells with staged interleukin-12 secretion prior to surgery in patients with ductal carcinoma in situ.
Enrolled patients with HER-2/neu-positive ductal carcinoma in situ (N=13) who received 4 weekly pre-operative vaccinations directly into lymph nodes.
Vaccine consisted of autologous DC1-type dendritic cells activated with IFN-gamma and lipopolysaccharide to secrete high levels of interleukin-12p70 and pulsed with HER-2/neu HLA class I and II peptides.
Vaccination induced peptide-specific sensitization in 85% of CD4+ and 80% of CD8+ T cells, inverted the inhibitory CTLA-4 to CD28 ratio on CD8+ T cells, and triggered tumor-lytic antibodies.
Seven of 11 evaluable patients (64%) showed markedly decreased HER-2/neu expression in surgical specimens along with measurable reductions in residual ductal carcinoma in situ.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Clinical trial demonstrates potent immune responses and tumor immunoediting in HER-2-positive ductal carcinoma in situ, highlighting dendritic cell vaccines for early breast cancer.

Cite This Study

Czerniecki et al. (2007) studied this question.

synapsesocial.com/papers/6a73a4f1aa90adf506fb7268 https://doi.org/10.1158/0008-5472.can-06-4038

View Full Paper

Ask AI

Bookmark

Implication

Clinical trial demonstrates potent immune responses and tumor immunoediting in HER-2-positive ductal carcinoma in situ, highlighting dendritic cell vaccines for early breast cancer.

Targeting HER-2/ neu in Early Breast Cancer Development Using Dendritic Cells with Staged Interleukin-12 Burst Secretion

Key Points

Discussion

Implication

Cite This Study

Targeting HER-2/ neu in Early Breast Cancer Development Using Dendritic Cells with Staged Interleukin-12 Burst Secretion

Key Points

Discussion

Implication

Cite This Study

Also Consider

Also Consider